Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 21, 2017. The report details the presentation of positive results from the Phase III Zoster-048 clinical study regarding GSK's candidate shingles vaccine, Shingrix (HZ/su), at the CDC's Advisory Committee on Immunization Practices (ACIP) meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a clinical update and does not contain financial statements or performance metrics.
Material Changes and Clinical Results
- Study Objective Met: The Zoster-048 study demonstrated that Shingrix induces a strong immune response in older adults (aged 65+) who were previously vaccinated with the live-attenuated zoster vaccine (ZVL) at least five years prior.
- Non-Inferiority: The immune response in previously vaccinated individuals was non-inferior to that of individuals without prior exposure to ZVL.
- Safety Profile: Shingrix was well-tolerated in both study groups up to one month after the second dose, with no clinically significant safety signs observed.
- Historical Efficacy: The filing references prior Phase III studies (ZOE-50 and ZOE-70) where Shingrix demonstrated efficacy against shingles above 90% across various age groups (>50, >70, >80) with sustained efficacy over four years.
Guidance, Outlook, and Risks
Regulatory Status: Shingrix is not currently approved for use anywhere in the world. Regulatory submissions were made to the FDA (October 2016), Canadian and European authorities (November 2016), and Japanese authorities (April 2017).
Management Commentary: Dr. Thomas Breuer, Senior Vice President and Chief Medical Officer of GSK Vaccines, stated that the results indicate Shingrix could be an option for adults over 50 seeking revaccination if recommended by policymakers.
Future Outlook: GSK expects the data to inform policymaking decisions regarding revaccination. Additional trials are underway for high-risk populations, including solid and hematological cancer patients and transplant recipients.
Risks: The filing includes a cautionary statement that forward-looking projections are subject to risks and uncertainties, including those described in the company's 2016 Annual Report on Form 20-F, which may cause actual results to differ materially.
Key Facts for Investor Verification
- Confirm the current regulatory approval status of Shingrix in the US, EU, and other major markets as of the filing date.
- Verify the timeline for potential FDA approval and market launch following the submission of the Zoster-048 data.
- Assess the potential market impact of revaccination policies for patients previously treated with ZVL.
- Review the results of ongoing trials in immunocompromised populations to evaluate the full scope of the vaccine's utility.